Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression
NCT06341426Phase 2Active, not recruiting
- Sponsor
- University Health Network
- Start
- Feb 2024
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in treatment-resistant depression (TRD) (2 arms), sponsored by University Health Network. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 8 weeks. Started Feb 2024; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06341426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06341426.